REYATAZ CAPSULE

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

ATAZANAVIR (ATAZANAVIR SULFATE)

Beschikbaar vanaf:

BRISTOL-MYERS SQUIBB CANADA

ATC-code:

J05AE08

INN (Algemene Internationale Benaming):

ATAZANAVIR

Dosering:

150MG

farmaceutische vorm:

CAPSULE

Samenstelling:

ATAZANAVIR (ATAZANAVIR SULFATE) 150MG

Toedieningsweg:

ORAL

Eenheden in pakket:

60

Prescription-type:

Prescription

Therapeutisch gebied:

HIV PROTEASE INHIBITORS

Product samenvatting:

Active ingredient group (AIG) number: 0149741002; AHFS:

Autorisatie-status:

CANCELLED POST MARKET

Autorisatie datum:

2022-04-28

Productkenmerken

_ _
_ _
_Page 1 of 77_
PRODUCT MONOGRAPH
PR REYATAZ
®
Atazanavir capsules
150, 200 and 300 mg
(as atazanavir sulfate)
Azapeptide Inhibitor of HIV-1 Protease
Bristol-Myers Squibb Canada Co.
Date of Preparation:
Montreal, Canada
December 3, 2003
Date of Revision:
April 28, 2020
®
Registered trademark of Bristol-Myers Squibb Holdings Ireland used
under licence by Bristol-Myers Squibb
Canada Co.
CONTROL NUMBER: 236039
_ _
_ _
_Page 2 of 77_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................22
DOSAGE AND ADMINISTRATION
..............................................................................39
OVERDOSAGE
.................................................................................................................41
ACTION AND CLINICAL PHARMACOLOGY
............................................................42
STORAGE AND STABILITY
..........................................................................................46
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................47
PART II : SCIENTIFIC INFORMATION
...............................................................................48
PHARMACEUTICAL INFORMATION
..........................................................................48
CLINICAL TRIALS
...........................................